Solid Biosciences Inc. entered into a securities purchase agreement with certain institutional accredited investors to issue common stock and Pre-Funded warrants for a aggregate proceeds of.
Depth of Field: Apertura Flashes AAV Capsids for Neurological Gene Therapy Delivery genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Valneva announces that the 90 to 110 million euros of other operating income linked to the potential sale of the Priority Review Voucher , which were previously expected by the end of 2023, are now.
21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer
21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer